TUBIZE (ATTR) Overview
Financière de Tubize is a single-asset ("mono") holding company. Its only material investment is a 36.29% stake in UCB SA (30 June 2026), the Brussels-headquartered biopharmaceutical group focused on immunology and neurology. Tubize is UCB's reference shareholder. It brings together descendants of UCB founder Emmanuel Janssen and like-minded long-term investors to give UCB a stable, long-horizon anchor shareholder. Tubize has no operating business. Its income statement is UCB's annual dividend less a small cost base, and its balance sheet is the UCB block. Tubize became debt-free in May 2025 and keeps adding to its UCB stake in small increments. It pays out roughly half of its profit as a progressive dividend. Since 2025 its board has been professionalised around biopharma expertise under independent chair Bruno Holthof. For investors, TUB is a leveraged-free, discounted proxy for UCB. The holding discount is the key valuation variable.
Company's own characterisation. Across its regulated releases and corporate descriptions, Tubize presents itself as the reference shareholder of UCB. It groups family shareholders descended from founder Emmanuel Janssen with others who share their long-term view, and it aims to give UCB the stability it needs to invest in new medicines for patients with severe diseases (World Economic Forum organisation profile; company descriptions on Lightyear).
What the company does. Tubize owns and manages one asset: about 70.6 million UCB shares (derived: €102.3M dividend received in 2026 ÷ €1.45 per UCB share). Its activities are:
-
Shareholder stewardship. It is represented on UCB's board and audit committee. Tubize's H1 2026 report states that its board keeps informed of UCB's activities and management through these representatives. Stefaan Heylen joined the UCB board in March 2024 as a Tubize representative.
-
Capital allocation. It reinvests part of the UCB dividend in additional UCB shares (24,487 in 2025; 15,783 in H1 2026). It repays acquisition debt (fully repaid May 2025). It distributes dividends to its own shareholders (€48.1M paid in 2026).
-
Governance of the family concert. It manages relations with family shareholders. This role was assigned to Vice-Chair Cyril Janssen in August 2025.
Business and revenue model.
Value-chain position. Tubize sits at the top of the ownership chain of a fully integrated biopharma company. UCB discovers, develops, manufactures and commercialises medicines in immunology (Bimzelx, Cimzia, Evenity via Amgen partnership) and neurology/rare disease (Briviact, Vimpat, Fintepla, Rystiggo, Zilbrysq, Kygevvi). Tubize itself has no customers. Economically, its "end-market" is UCB's: specialty biopharma, mainly sold in the United States, then Europe and international markets.
Independent characterisation. Tubize is best understood as a closed-end, permanently capitalised vehicle for UCB equity. Its economic drivers are:
-
the UCB share price, which drives net asset value (NAV);
-
UCB's dividend, which drives Tubize earnings and its own dividend;
-
the market discount applied to Tubize versus look-through NAV (about 47% at mid-October 2026, derived).
Unlike Belgian peers Sofina, GBL or Ackermans & van Haaren, Tubize has no diversification. Its revenue and capital returns are a lagged, damped derivative of UCB's capital-return policy. UCB pays a modest dividend (€1.45/share for FY2025), so Tubize's earnings yield on market value is low. Its trailing P/E is structurally high, around 83x at €173.10 (derived). Earnings multiples are therefore of limited use, and NAV discount analysis is the relevant valuation framework.
Strategy
Stated strategy (paraphrased from company releases).
-
Act as UCB's long-term, stable reference shareholder, keeping a stake of about 36%.
-
Support UCB's growth and its investment in new medicines.
-
Strengthen biopharma expertise on the Tubize board so it can be an informed, constructive owner.
-
Promote a sustainable biopharma ecosystem in Belgium, the UK and other geographies relevant to UCB (chair's statement, 29 Apr 2025).
-
Keep the balance sheet strong. Quartr's summary of Tubize's 2025 annual presentation references strategic reserves supporting UCB while maintaining the 36% stake.
Initiatives in the last 24 months
Cost programmes: none disclosed. The cost base is about €2–3M a year.
ESG commitments: none at Tubize level.
Medium-term financial targets: none published. Tubize gives no guidance. Its H1 2026 outlook only states that it will stay attentive to geopolitical developments and their possible effect on UCB and on its own results.
Products & Services
Tubize has no products or services of its own. Its "portfolio" is one listed equity stake. For completeness, the economic exposure is catalogued through UCB's commercial portfolio. Figures are UCB-reported.
5a. Tubize's direct offering
5b. Look-through UCB portfolio (principal brands)
Named pipeline bets (look-through): glovadalen (UCB0022, Parkinson's, positive Phase 2a); bepranemab (Alzheimer's, Fast Track); galvokimig (atopic dermatitis, Phase 2b); bimekizumab in palmoplantar pustulosis (Phase 3); STACCATO alprazolam (prolonged seizures, headline results expected 2026). Source: UCB FY2025 results, 26 Feb 2026.
Product Portfolio
| Offering | Description | Target "customer" | Pricing |
|---|---|---|---|
TUB ordinary share | Listed share giving look-through exposure to about 1.59 UCB shares per TUB share (derived: 70.55M ÷ 44.51M) | Long-term investors, family holders, index funds (e.g., iShares EURO STOXX Small; FTSE All-World constituents) | Market price; annual gross dividend €1.08 (FY2025) |
| Brand | Molecule / class | Therapeutic area | Status / data point | Source |
|---|---|---|---|---|
BIMZELX | bimekizumab, IL-17A/IL-17F inhibitor | Psoriasis, psoriatic arthritis, axial SpA, hidradenitis suppurativa | Net sales €2.23bn in FY2025 (more than tripled); €1.528bn in H1 2026; peak-sales guidance raised to at least €7bn; protection to 2037; BE BOLD was the fourth head-to-head superiority study | UCB FY2025 and H1 2026 releases; H1 2026 call |
EVENITY | romosozumab (with Amgen) | Osteoporosis | One of five "growth drivers" | UCB FY2025 release |
FINTEPLA | fenfluramine | Rare epilepsies (Dravet, LGS; CDKL5 Phase 3 GEMZ positive Jun 2025) | Next major loss of exclusivity flagged for 2033 | UCB H1 2025 / H1 2026 materials |
RYSTIGGO | rozanolixizumab, FcRn inhibitor | Generalised myasthenia gravis; ocular MG Phase 3 started Q2 2026 | Growth driver | UCB H1 2026 release |
ZILBRYSQ | zilucoplan, C5 inhibitor | Generalised myasthenia gravis | Growth driver | UCB FY2025 release |
KYGEVVI | doxecitine and doxribtimine | Thymidine kinase 2 deficiency (TK2d) | Approved in US; EU positive opinion | UCB FY2025 release |
BRIVIACT | brivaracetam | Epilepsy | €758M net sales in FY2025 (+11%); US exclusivity ended Feb 2026, EU Aug 2026 | UCB FY2025 (Investing.com) |
CIMZIA | certolizumab pegol | Immunology | Price erosion flagged | UCB H1 2025 summary |
VIMPAT / KEPPRA | lacosamide / levetiracetam | Epilepsy (mature, genericised) | Mature brands | UCB reports |
Financial Narrative
Tubize reports under Belgian GAAP at statutory level and publishes annual and half-year financial reports. Ratios are derived.
6a. Income statement
Sources: TipRanks (FY2021–FY2024 line items); Tubize releases (FY2023–FY2025 profit and DPS); Beursgenoten (FY2025 operating result about -€3M); EPS FY2025 derived as 93.2 ÷ 44.51.
Note on FY2020. Net income was €260.5M (EPS €5.85, TipRanks). This is a non-recurring outlier and is excluded from trend analysis.
Margins. Gross, operating, EBITDA and net margins are not meaningful because operating revenue is about zero. A useful substitute is the profit-to-dividend-received conversion. In H1 2026, profit of €100.8M on €102.3M received is about 98.5% (derived). Corporate costs and interest absorb only about 1–3% of gross income.
Revenue CAGR. Not meaningful. The CAGR of net income FY2021–FY2025 is 2.75% (derived).
6b. Half-year income (seasonality: UCB pays its dividend in Q2)
Sources: Tubize H1 2025 and H1 2026 releases; Dutch H1 2026 report (interest). The H1 2024 UCB DPS of €1.36 is UCB's FY2023 dividend, implied from the 2.2% increase to €1.39.
Full-year profit falls below H1 profit (FY2025 €93.2M versus H1 2025 €95.6M). This is because H2 carries only costs and no dividend income.
6c. Balance sheet
Sources: Tubize releases (debt, FY2025 equity, solvency, purchases). Equity for FY2022–FY2024 is derived by rolling FY2025 equity back by net profit less dividends paid (2023 €38.3M, 2024 €43.2M, 2025 €46.3M). Treat it as indicative.
H1 2026: equity €1,986.3M, solvency ratio 99.98%, no bank debt (H1 2026 report summary, Quartr).
Cash and equivalents: small working balance. Exact figure n/d in sources reviewed.
Goodwill and intangibles: nil.
Working capital: minimal. Lightyear reports a TTM current ratio of about 3.2x.
Net debt: about nil or slightly negative from mid-2025.
Short/long-term debt split: short-term bank lines historically. The lines were secured by pledges over UCB shares (pledge over 95,000 UCB shares through 30 June 2026 per the Dutch H1 2026 report).
6d. Cash flow (holding-level, derived from disclosed items)
Sources: Tubize releases. Dividends paid are derived as prior-year DPS × 44.51M shares. FY2025 dividends paid matches the €46.3M disclosed in the H1 2025 report. The 2023 debt drawdown financed the 1.04M-share UCB purchase.
-
2026 year to date: €102.3M received, €48.1M paid, €4.05M of UCB shares bought.
-
Share buybacks: none disclosed.
6e. Ratios
All ratios derived. Lightyear independently shows TTM ROE of 5.00%.
ROA is about equal to ROE given negligible liabilities. ROIC, interest coverage, asset turnover and cash conversion cycle are not meaningful for a holding with no operations. Interest coverage moved to "infinite" once interest fell to nil in H1 2026.
Trend commentary. Three phases stand out:
-
Deleveraging, 2017–2022. Debt fell from €192M (end-2017) to €47.8M (end-2022) while the dividend rose.
-
Opportunistic re-leveraging, 2023. Tubize bought over 1 million UCB shares during UCB's 2023 share-price trough. This raised the stake by 54bp to 36.24% and lifted debt to €79.2M. In hindsight it was a well-timed move, because UCB's share price subsequently multiplied on the Bimzelx launch.
-
Rapid deleveraging to zero, 2024–2025. Purchases were scaled back to token amounts (about €4M a year).
Profit growth is mechanical: roughly UCB DPS growth plus the stake increment, minus interest. The board has prioritised dividend growth (+12.8%, +7.2%, +3.85%) over large stake increases since 2024. Dividend growth decelerated in line with UCB's own 2.2% and 4.3% DPS increases.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Net profit (EUR Mn) | 83.6 | 85.2 | 88.2 | 90.1 | 93.2 |
Profit YoY growth (%) | — | 1.9 | 3.5 | 2.2 | 3.5 |
Contribution to total income (%) | 100 | 100 | 100 | 100 | 100 |
UCB stake at year end (%) | — | 35.70 | 36.24 | 36.27 | 36.28 |
Revenue by Segment and Per-Share Data
| Metric | FY2024 | FY2025 |
|---|---|---|
UCB revenue (EUR Mn) | 6,150 | 7,740 |
UCB net sales (EUR Mn) | — | 7,390 |
UCB adjusted EBITDA (EUR Mn) | — | 2,640 |
UCB core EPS (EUR) | — | 9.99 |
UCB dividend per share (EUR) | 1.39 | 1.45 |
Revenue by Segment
| Metric (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
UCB revenue | 3,487 | 4,270 |
UCB adjusted EBITDA | 1,033 | 1,740 |
Bimzelx net sales | 799 | 1,528 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue, operating (EUR Mn) | 0.00 | 0.01 | 0.00 | 0.01 | 0.00 |
Operating result, holding costs (EUR Mn) | -1.54 | -1.82 | -2.14 | -2.24 | -3.0 |
Financial income, net of interest (EUR Mn) | 85.14 | 86.99 | 90.30 | 92.34 | — |
Pre-tax income (EUR Mn) | 83.6 | 85.2 | 88.2 | 90.1 | 93.2 |
Net income (EUR Mn) | 83.6 | 85.2 | 88.2 | 90.1 | 93.2 |
EPS basic, EUR | 1.88 | 1.91 | 1.98 | 2.02 | 2.09 |
EPS diluted, EUR | 1.88 | 1.91 | 1.98 | 2.02 | 2.09 |
Gross dividend per share, EUR | — | 0.86 | 0.97 | 1.04 | 1.08 |
DPS growth (%) | — | — | 12.8 | 7.2 | 3.85 |
Payout ratio, declared DPS / EPS (%) | — | 45.0 | 49.0 | 51.5 | 51.7 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDividends & Capital Returns and Per-Share Data
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
H1 profit (EUR Mn) | 92.9 | 95.6 | 100.8 |
UCB dividend received (EUR Mn) | — | 98.1 | 102.3 |
UCB DPS received (EUR) | 1.36 | 1.39 | 1.45 |
Interest expense (EUR Mn) | — | 0.719 | 0.0 |
Balance Sheet and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Bank borrowings (EUR Mn) | 47.8 | 79.2 | 41.3 | 0.0 |
Shareholders' equity (EUR Mn) | 1,741.9 | 1,791.8 | 1,838.7 | 1,885.6 |
Solvency ratio (%) | — | — | — | 97.49 |
UCB shares acquired in year (thousand) | — | 1,043.9 | 53.7 | 24.5 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansDividends & Capital Returns
| Metric (EUR Mn) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
UCB dividend received | — | — | 98.1 |
Dividends paid to TUB shareholders | 38.3 | 43.2 | 46.3 |
UCB share purchases (capex equivalent) | — | — | 4.4 |
Net bank debt repayment / (drawdown) | -31.4 | 37.9 | 41.3 |
Margin Analysis (%) and Financial Ratios (x)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE on average equity (%) | 5.0 | 5.0 | 5.0 |
Debt / equity (%) | 4.4 | 2.2 | 0.0 |
Net debt / profit (x) | 0.90 | 0.46 | 0.00 |
Revenue by Region (%)
| Region | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Belgium, Tubize dividend income (% of total) | 100 | 100 | 100 |
All other regions, Tubize (% of total) | 0 | 0 | 0 |
Share Price & Returns
| Date | TUB close (EUR) | Source |
|---|---|---|
3 Oct 2025 | ≈218.00 | Trivano (KBC note) |
31 Dec 2025 | ≈208.9 | Derived from €9.30bn market cap ÷ 44.51M |
30 Jun 2026 | 231.00 | H1 2026 report |
8 Jul 2026 | 214.80 | EODData |
6 Aug 2026 | 193.30 | Trivano |
24 Aug 2026 | 188.40 | Trivano |
28 Sep 2026 | 179.40 | Trivano |
12 Oct 2026 | 173.10 | Trivano |
Market Valuation
| Metric | FY2025 |
|---|---|
Market cap at year end (EUR Bn) | 9.30 |
Valuation Multiples
| Multiple | TUB | Comment |
|---|---|---|
Trailing P/E (FY2025 EPS €2.09) | ≈82.8x | Structurally high for a dividend-receiving holding |
P/B (H1 2026 equity €1,986.3M) | ≈3.9x | Book carries UCB below market value |
Dividend yield (€1.08 gross) | ≈0.62% | — |
Discount to look-through NAV | ≈47% | — |
UCB P/E (look-through) | ≈17.7–17.8x | Ad-hoc News, Oct 2026 |
Analyst Ratings & Targets
| Broker | Date | Rating | Target (EUR) |
|---|---|---|---|
Degroof Petercam | 24 Aug 2026 | Buy (upgraded from Hold) | 286 |
KBC Securities | 3 Oct 2025 | Accumulate (downgraded from Buy) | 217 |
Consensus (Trivano) | Aug 2026 | — | 251.50 average |
Consensus (Stockopedia, earlier) | — | Hold | 230.50 |
Per-Share Data
| Metric | FY2018 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross DPS (EUR) | 0.56 | 0.86 | 0.97 | 1.04 | 1.08 |
Analyst Conclusions
Management guidance. None. Tubize's 2026 income is effectively locked in. The FY2025 UCB dividend of €1.45 produced €102.3M, already received. H1 2026 profit was €100.8M, so FY2026 profit will likely land near €98M (H1 less H2 costs; analyst inference, not guidance). That supports another modest dividend increase in 2027 if UCB raises its FY2026 dividend.
Look-through consensus drivers. UCB guides FY2026 revenue growth in the low-to-mid-teens and adjusted EBITDA growth in the mid-teens to low-20s at constant exchange rates (H1 2026 call). Bimzelx peak sales are guided at least €7bn. Broker targets on UCB range from €260 (Barclays, Hold) to €304 (ING), against about €205 currently.
Bull case
-
Double leverage to UCB recovery. If UCB re-rates toward the €260–304 broker range (+27–48%) and the TUB discount stays constant, TUB rises proportionally. If the discount also narrows from about 47% toward 35–40%, the upside compounds.
-
Dividend acceleration. UCB's earnings are inflecting (H1 2026 EBITDA +68%, core EPS €6.84). A step-up in UCB's payout would flow almost one-for-one to Tubize's profit and dividend, given about 98% conversion.
-
Balance-sheet optionality. Tubize is debt-free and has shown it can buy aggressively on dips (2023). It can accrete UCB shares cheaply while UCB trades about 30% below its high.
Bear case
-
Concentration risk materialising. Briviact loss of exclusivity in 2026, US Bimzelx net-price pressure and rising R&D (about 25% of sales) could cap UCB's share price. The September–October 2026 derating shows the sensitivity.
-
Sticky or widening discount. Family control, a 0.6% yield, no buybacks and placement overhang (November 2025) give investors little reason to close the 47% gap.
-
Low cash return on market value. Profit growth of about 3% a year and a P/E above 80x leave TUB reliant entirely on UCB price appreciation for returns.
Key catalysts and monitorables (next 12 months)
Analyst verdict. Financière de Tubize is a clean, almost frictionless vehicle for UCB equity. It now carries no debt, a cost base under €3M, a 36.29% stake and a board that has been deliberately upgraded with biopharma expertise since 2025. Its reported numbers are a slow-moving reflection of UCB's conservative dividend policy: profit has risen from €83.6M in FY2021 to €93.2M in FY2025, and the dividend from €0.86 to €1.08 per share. These numbers say little about the value being created underneath. That value sits in UCB's transformation into an immunology leader. Bimzelx sales doubled to €1.53bn in H1 2026, UCB's adjusted EBITDA margin reached 40.7%, and management guides peak Bimzelx sales of at least €7bn with exclusivity to 2037.
The investment case therefore rests on two variables: the UCB share price and the Tubize discount. At €173.10, TUB implies a look-through NAV of about €325 per share, a discount of about 47%. That discount sits at the wide end of what family-controlled Belgian holdings typically carry. It coincides with UCB itself trading roughly 30% below its 52-week high on Briviact loss of exclusivity and US pricing concerns. This double compression is what drove Degroof Petercam's August 2026 upgrade to Buy (€286 target).
The counterweights are real. Tubize offers no buybacks, a sub-1% yield, thin liquidity and visible family-branch selling (the ~€172M placement in November 2025). Its fortunes are wholly hostage to a single biopharma company. It is unsuitable for income or diversification mandates. Stance: constructive, discount-driven; position sizing should treat TUB as a UCB position with added discount volatility.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure | Compensation |
|---|---|---|---|
Eric Nys | Managing Director / CEO | Active at least since 2023 (AGM correspondent in 2023 convocation) | €201.0k per Yahoo Finance (year and composition n/d) |
Anne Sophie Pijcke | General Manager / Director | Long-standing; IR contact on FY2018 release | €37k per Yahoo Finance (year n/d) |
Anne Keup | Management board member (per ShareCompany/Beursgenoten) | — | — |
Board of Directors — Prof. Dr Bruno Holthof
| Name | Role | Notes |
|---|---|---|
Prof. Dr Bruno Holthof | Chair (since 25 Apr 2025) | Previously independent director. Aims to strengthen biopharma expertise and support a biopharma ecosystem in Belgium, the UK and UCB's other key geographies (29 Apr 2025 release). |
Cyril Janssen | Vice-Chair (since 1 Aug 2025); via Nikita SRL | Re-appointed April 2025 to the 2029 AGM. Manages family-shareholder relations. Born 1971. Co-controls Financière Eric Janssen. |
Iris Löw-Friedrich | Director (since Sep 2025) | MD, PhD, internist. Former member of the Boehringer Ingelheim Board of Managing Directors (Jan 2020–Sep 2024, Human Pharma). Boards: Fresenius, Sobi, Evotec; Munich Re supervisory board. Born 1960. |
Eric Cornut | Director (profile published for 24 Apr 2026 AGM) | Former pharma executive; detailed bio n/d in sources reviewed. |
Evelyn du Monceau | Director | Family director; born 1950; renewal proposed 2023 AGM. |
Charles-Antoine Janssen | Director | Family director; born 1971. |
Cédric van Rijckevorsel | Director | Family director. |
Cynthia Favre d'Echallens | Director | — |
Tanguy du Monceau | Director | Family director. |
Sandrine Flory | Director | — |
Carinne (Knoche-)Brouillon | Former director | Appointed Sep 2025; resigned effective 24 Apr 2026. |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
25 Apr 2025 | Gaëtan Hannecart leaves; Bruno Holthof becomes chair | Generational handover and professionalisation |
1 Aug 2025 | Cyril Janssen named Vice-Chair | Family-relations role |
Sep 2025 | Löw-Friedrich and Brouillon appointed | Biopharma expertise |
24 Apr 2026 | Brouillon resigns; Eric Cornut proposed | Board refresh |
Mar 2024 | Stefaan Heylen joins UCB board for Tubize | Reinforced representation at UCB |
Major Shareholders
| Holder | Stake (%) |
|---|---|
Financière Eric Janssen SPRL | 19.15 |
Daniel Janssen | 13.21 |
Altai Invest SA | 11.16 |
Barnfin SA | 8.80 |
Top-4 combined | 52.32 |
Competitive Landscape
Key Competitors
| Peer | Profile | Relative positioning versus Tubize |
|---|---|---|
Solvac | Family duo-holding (Solvay, Syensqo) | Also a family-controlled holding at a deep discount; press noted it underperformed its underlying assets in 2025 while Tubize re-rated |
Sofina | Diversified, growth/private-equity focused | Diversified, actively managed |
Groupe Bruxelles Lambert (GBL) | Diversified listed and private holding | Larger, buybacks, active rotation |
Ackermans & van Haaren | Diversified (marine, banking, real estate) | Operating-company mix |
Gimv | Private-equity investor | Different asset class |
KBC Ancora / Cera | Mono-holding of KBC shares | Closest structural analogue (mono-holding) |
Brederode | Listed PE fund-of-funds holding | Discount vehicle |
Solvac / Tubize-type family holdings | Belgian control vehicles | Same discount drivers |
Key Competitors by Competitor
| Competitor | Competing franchise | Arena |
|---|---|---|
AbbVie | Skyrizi (IL-23), Humira | Psoriasis, PsA, HS |
Johnson & Johnson | Tremfya, Stelara | Psoriasis, PsA |
Novartis | Cosentyx (IL-17A) | Psoriasis, PsA, axSpA, HS |
Eli Lilly | Taltz (IL-17A) | Psoriasis, PsA, axSpA |
Amgen | Otezla; also Evenity partner | Psoriasis (oral), osteoporosis |
argenx | Vyvgart (FcRn) | Myasthenia gravis versus Rystiggo |
AstraZeneca / Alexion | Ultomiris, Soliris (C5) | Myasthenia gravis versus Zilbrysq |
Jazz Pharmaceuticals | Epidiolex | Rare epilepsies versus Fintepla |
Eisai, Sunovion and generics | Antiepileptics | Epilepsy (post-Briviact LOE) |
Peer Comparison FY2025
| Company | Revenue FY2024 | Revenue growth FY2025 | Adj. EBITDA margin | R&D intensity |
|---|---|---|---|---|
UCB | €6.15bn | +26% (to €7.74bn) | 34% reported (31.4% underlying) FY2025 | About 25% of net sales (FY2026 guide) |



